Want to see ARTV full AI Analyst Report?
ARTV Stock Chart & Stats
$12.55
$0.32(3.02%)
At close: 4:00 PM EST
$12.55
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$1.69 - $14.53
Previous CloseN/A
Volume23.16K
Average Volume (3M)614.64K
Market Cap
$452.36M
Enterprise Value$234.99M
Total Cash (Recent Filing)$86.78M
Total Debt (Recent Filing)$10.26M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 27, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding48,588,200
10 Day Avg. Volume523,609
30 Day Avg. Volume614,639
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-352.84
Enterprise Value/Ebitda-2.78
Forecast
1Y Price Target
$35.80Price Target Upside185.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress / Phase 3 AlignmentRegulatory alignment and strong Phase 2a efficacy materially de-risk the development pathway. A clear Phase 3 registrational plan increases the probability of a successful BLA-enabling program, strengthens future partnering and commercialization prospects, and supports long-term value creation if results hold.
Material Capital RaiseA large $300M equity raise meaningfully extends funding for clinical programs and reduces near-term liquidity pressure. For a pre-revenue biotech, this durable capital base supports initiation and completion of late-stage trials and gives management time to advance regulatory milestones before needing additional financing.
Low Leverage / Modest DebtA low debt burden preserves financial flexibility and limits fixed financing costs for a pre-revenue, R&D-intensive company. Modest leverage is supportive of taking on prolonged clinical programs without significant interest or covenant pressure, making it easier to prioritize R&D investments over near-term cash flow.
Bears Say
Sustained Cash BurnPersistently large negative operating and free cash flow indicate the business consumes substantial cash to fund R&D. Over a multi‑month horizon this necessitates repeated access to capital markets or partnerships, diluting shareholders or increasing financing risk if market conditions worsen or trial timelines slip.
Absent/immaterial RevenueWith no meaningful recurring revenue, the company cannot internally fund development and is fully reliant on external financing and milestone deals. This structural lack of revenue raises execution risk and makes the firm sensitive to capital market cycles during the critical run-up to potential commercialization.
Executive Turnover & Role ConsolidationRecent leadership shifts and the CEO taking on principal financial duties create governance and execution risk during a pivotal development phase. CFO vacancy and role consolidation may strain financial oversight and distract management at a time when tight capital management and clinical program execution are essential.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.69 and its highest was $14.53 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $452.36M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Aug 27, 2026 which is in 49 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on May 08, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.08.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.63.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 48,588,200 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -13.019%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.80 (185.26% Upside)
$35.80 (185.26% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $103.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
500.00%
12-Months-Change
Fundamentals
Return on Equity
-73.16%
Trailing 12-Months
Asset Growth
-44.60%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$35.80
▲(185.26% Upside)
Technical Analysis
Ownership Overview
55.18% Insiders
1.17% Mutual Funds
30.95% Other Institutional Investors
11.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---